Lil­ly's weight loss drug Zep­bound gen­er­ates $175M with­in weeks as Moun­jaro sales al­so soar

Eli Lil­ly’s weight loss drug Zep­bound has pulled in $175.8 mil­lion in rev­enue since its ap­proval in No­vem­ber, the In­di­anapo­lis phar­ma said Tues­day in its fourth-quar­ter earn­ings re­port.

The drug, which on­ly be­came avail­able on Dec. 5, was ap­proved by the FDA for adult pa­tients with obe­si­ty or over­weight with weight-re­lat­ed co­mor­bidi­ties. Both Zep­bound and Moun­jaro are for­mu­la­tions of tirzepatide but have dif­fer­ent ap­provals: Zep­bound for obe­si­ty and Moun­jaro for type 2 di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER